title: Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity.
abstract: Nucleoside analogs are efficacious cancer chemotherapeutics due to their incorporation into tumor cell DNA. However, they exhibit vastly different antitumor efficacies, suggesting that incorporation produces divergent effects on DNA replication. Here we have evaluated the consequences of incorporation on DNA replication and its fidelity for three structurally related deoxyguanosine analogs: ganciclovir (GCV), currently in clinical trials in a suicide gene therapy approach for cancer, D-carbocyclic 2'-deoxyguanosine (CdG) and penciclovir (PCV). GCV and CdG elicited similar cytotoxicity at low concentrations, whereas PCV was 10-100-fold less cytotoxic in human tumor cells. DNA replication fidelity was evaluated using a supF plasmid-based mutation assay. Only GCV induced a dose-dependent increase in mutation frequency, predominantly GC-->TA transversions, which contributed to cytotoxicity and implicated the ether oxygen in mutagenicity. Activation of mismatch repair with hydroxyurea decreased mutations but failed to repair the GC-->TA transversions. GCV slowed S-phase progression and CdG also induced a G2/M block, but both drugs allowed completion of one cell cycle after drug treatment followed by cell death in the second cell cycle. In contrast, PCV induced a lengthy early S-phase block due to profound suppression of DNA synthesis, with cell death in the first cell cycle after drug treatment. These data suggest that GCV and CdG elicit superior cytotoxicity due to their effects in template DNA, whereas strong inhibition of nascent strand synthesis by PCV may protect against cytotoxicity. Nucleoside analogs based on the carbohydrate structures of GCV and CdG is a promising area for antitumor drug development.
authors.affiliation: Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.
authors.forename: Jessica J
authors.initials: JJ
authors.lastname: O'Konek
authors.forename: Brendon
authors.initials: B
authors.lastname: Ladd
authors.forename: Sheryl A
authors.initials: SA
authors.lastname: Flanagan
authors.forename: Mike M
authors.initials: MM
authors.lastname: Im
authors.forename: Paul D
authors.initials: PD
authors.lastname: Boucher
authors.forename: Tico S
authors.initials: TS
authors.lastname: Thepsourinthone
authors.forename: John A
authors.initials: JA
authors.lastname: Secrist
authors.forename: Donna S
authors.initials: DS
authors.lastname: Shewach
mesh_terms: D000212:Acyclovir / Q000031:analogs & derivatives / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001483:Base Sequence; D002241:Carbohydrates / Q000737:chemistry*; D002453:Cell Cycle / Q000187:drug effects*; D016923:Cell Death / Q000187:drug effects*; D045744:Cell Line, Tumor; D053843:DNA Mismatch Repair; D004261:DNA Replication / Q000187:drug effects*; D003849:Deoxyguanosine / Q000819:agonists / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000494:pharmacology; D015774:Ganciclovir / Q000494:pharmacology*; D041722:Genes, Transgenic, Suicide; D006147:Guanine; D045325:HCT116 Cells; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation
chemical_list: D000970:Antineoplastic Agents; D002241:Carbohydrates; C075251:carbocyclic 5'-nor-2'-deoxyguanosine; C053539:penciclovir; D006147:Guanine; D003849:Deoxyguanosine; D015774:Ganciclovir; D000212:Acyclovir